In patients with hereditary breast and ovarian cancer (HBOC) syndrome, who are heterozygously mutated in either BRCA1 or BRCA2, cancer‐initiating cells mostly undergo loss of wild‐type BRCA1/2 allele.11 This evidence concerns the gene BRCA2 and cancer.